DEXCOM INC (DC4.DE) Stock Price & Overview
FRA:DC4 • US2521311074
Current stock price
The current stock price of DC4.DE is 57.44 EUR. Today DC4.DE is up by 0.4%. In the past month the price decreased by -3.19%. In the past year, price decreased by -11.19%.
DC4.DE Key Statistics
- Market Cap
- 22.106B
- P/E
- 35.46
- Fwd P/E
- 25.93
- EPS (TTM)
- 1.62
- Dividend Yield
- N/A
DC4.DE Stock Performance
DC4.DE Stock Chart
DC4.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DC4.DE. When comparing the yearly performance of all stocks, DC4.DE is a bad performer in the overall market: 80.66% of all stocks are doing better.
DC4.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to DC4.DE. DC4.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
DC4.DE Earnings
On February 12, 2026 DC4.DE reported an EPS of 0.45 and a revenue of 1.26B. The company missed EPS expectations (-32.12% surprise) and missed revenue expectations (-0.9% surprise).
DC4.DE Forecast & Estimates
37 analysts have analysed DC4.DE and the average price target is 76 EUR. This implies a price increase of 32.32% is expected in the next year compared to the current price of 57.44.
For the next year, analysts expect an EPS growth of 36.69% and a revenue growth 12.64% for DC4.DE
DC4.DE Groups
Sector & Classification
DC4.DE Financial Highlights
Over the last trailing twelve months DC4.DE reported a non-GAAP Earnings per Share(EPS) of 1.62. The EPS increased by 12.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.94% | ||
| ROA | 13.19% | ||
| ROE | 30.46% | ||
| Debt/Equity | 0.47 |
DC4.DE Ownership
DC4.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1MDT | MEDTRONIC PLC | 14.49 | 108.279B | ||
| 2M6 | MEDTRONIC PLC | 14.3 | 98.217B | ||
| SHL | SIEMENS HEALTHINEERS AG | 14.86 | 43.744B | ||
| 1PHIA | KONINKLIJKE PHILIPS NV | 16.04 | 25.662B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 15.96 | 23.505B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 15.96 | 23.505B | ||
| BIM | BIOMERIEUX | 19.49 | 11.25B | ||
| DIA | DIASORIN SPA | 15.63 | 3.581B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 17.77 | 3.411B | ||
| 1AFX | CARL ZEISS MEDITEC AG - BR | 10.14 | 2.309B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 11.5 | 2.113B | ||
| DRW3 | DRAEGERWERK AG - PREF | 10.89 | 1.621B | ||
| DRW8 | DRAEGERWERK AG | 8.67 | 1.291B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DC4.DE
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
IPO: 2005-04-14
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA US
Employees: 11000
Phone: 13026365400
DEXCOM INC / DC4.DE FAQ
What does DEXCOM INC do?
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
What is the current price of DC4 stock?
The current stock price of DC4.DE is 57.44 EUR. The price increased by 0.4% in the last trading session.
What is the dividend status of DEXCOM INC?
DC4.DE does not pay a dividend.
What is the ChartMill rating of DEXCOM INC stock?
DC4.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is DC4.DE stock listed?
DC4.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the market capitalization of DC4 stock?
DEXCOM INC (DC4.DE) has a market capitalization of 22.11B EUR. This makes DC4.DE a Large Cap stock.